Zacks: Brokerages Anticipate Intec Pharma (NTEC) Will Announce Earnings of -$0.30 Per Share
Wall Street brokerages expect that Intec Pharma (NASDAQ:NTEC) will announce earnings of ($0.30) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Intec Pharma’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.32). Intec Pharma reported earnings of ($0.40) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 25%. The company is scheduled to report its next earnings results on Wednesday, November 21st.
On average, analysts expect that Intec Pharma will report full-year earnings of ($1.28) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($0.93). For the next year, analysts expect that the business will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.05) to ($0.68). Zacks’ EPS calculations are an average based on a survey of analysts that follow Intec Pharma.
A number of equities analysts have recently issued reports on NTEC shares. HC Wainwright set a $16.00 price target on Intec Pharma and gave the stock a “buy” rating in a research report on Thursday, August 16th. Oppenheimer set a $15.00 price target on Intec Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Roth Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Intec Pharma in a research report on Tuesday, June 26th. Finally, Zacks Investment Research downgraded Intec Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, May 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Intec Pharma currently has a consensus rating of “Buy” and a consensus target price of $12.25.
Several hedge funds have recently modified their holdings of NTEC. Acuta Capital Partners LLC grew its holdings in shares of Intec Pharma by 8.7% during the second quarter. Acuta Capital Partners LLC now owns 2,962,568 shares of the biotechnology company’s stock valued at $13,035,000 after buying an additional 238,285 shares during the last quarter. Prosight Management LP purchased a new stake in shares of Intec Pharma during the second quarter valued at $4,951,000. DAFNA Capital Management LLC purchased a new stake in shares of Intec Pharma during the second quarter valued at $2,502,000. Deutsche Bank AG grew its holdings in shares of Intec Pharma by 59.2% during the fourth quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 42,867 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Intec Pharma by 484.3% during the second quarter. Renaissance Technologies LLC now owns 88,898 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 73,684 shares during the last quarter. 44.63% of the stock is currently owned by institutional investors and hedge funds.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Story: What is a closed-end mutual fund (CEF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.